Chase, D. M., Hanna, M., Lim, J. T., Boyle, T. A. C., Guinter, M., Richey, M., . . . Golembesky, A. K. Niraparib as First-Line Maintenance Therapy in Patients with Stage III Ovarian Cancer and No Visible Residual Disease: AR1ZE Real-World Study. Adis, Springer Healthcare.
Chicago Style (17th ed.) CitationChase, Dana M., et al. Niraparib as First-Line Maintenance Therapy in Patients with Stage III Ovarian Cancer and No Visible Residual Disease: AR1ZE Real-World Study. Adis, Springer Healthcare.
MLA (9th ed.) CitationChase, Dana M., et al. Niraparib as First-Line Maintenance Therapy in Patients with Stage III Ovarian Cancer and No Visible Residual Disease: AR1ZE Real-World Study. Adis, Springer Healthcare.
Warning: These citations may not always be 100% accurate.